LifeVantage (LFVN) Competitors $12.37 +0.02 (+0.16%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$12.32 -0.05 (-0.44%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LFVN vs. XERS, ABUS, CDXC, ARVN, KALV, TRVI, KROS, VECT, PHAR, and VALNShould you be buying LifeVantage stock or one of its competitors? The main competitors of LifeVantage include Xeris Biopharma (XERS), Arbutus Biopharma (ABUS), ChromaDex (CDXC), Arvinas (ARVN), KalVista Pharmaceuticals (KALV), Trevi Therapeutics (TRVI), Keros Therapeutics (KROS), VectivBio (VECT), Pharming Group (PHAR), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry. LifeVantage vs. Xeris Biopharma Arbutus Biopharma ChromaDex Arvinas KalVista Pharmaceuticals Trevi Therapeutics Keros Therapeutics VectivBio Pharming Group Valneva LifeVantage (NASDAQ:LFVN) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends. Do analysts recommend LFVN or XERS? LifeVantage presently has a consensus target price of $30.50, suggesting a potential upside of 146.56%. Xeris Biopharma has a consensus target price of $6.10, suggesting a potential upside of 33.48%. Given LifeVantage's stronger consensus rating and higher possible upside, equities research analysts clearly believe LifeVantage is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeVantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more risk and volatility, LFVN or XERS? LifeVantage has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Which has stronger earnings & valuation, LFVN or XERS? LifeVantage has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifeVantage$212.15M0.73$2.94M$0.5622.09Xeris Biopharma$203.07M3.52-$62.26M-$0.38-12.03 Is LFVN or XERS more profitable? LifeVantage has a net margin of 3.46% compared to Xeris Biopharma's net margin of -33.69%. LifeVantage's return on equity of 34.29% beat Xeris Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets LifeVantage3.46% 34.29% 15.04% Xeris Biopharma -33.69%N/A -17.38% Does the MarketBeat Community prefer LFVN or XERS? LifeVantage received 76 more outperform votes than Xeris Biopharma when rated by MarketBeat users. Likewise, 77.97% of users gave LifeVantage an outperform vote while only 70.00% of users gave Xeris Biopharma an outperform vote. CompanyUnderperformOutperformLifeVantageOutperform Votes22377.97% Underperform Votes6322.03% Xeris BiopharmaOutperform Votes14770.00% Underperform Votes6330.00% Does the media prefer LFVN or XERS? In the previous week, LifeVantage had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 4 mentions for LifeVantage and 3 mentions for Xeris Biopharma. LifeVantage's average media sentiment score of 1.14 beat Xeris Biopharma's score of 0.68 indicating that LifeVantage is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeVantage 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in LFVN or XERS? 35.3% of LifeVantage shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 20.7% of LifeVantage shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryLifeVantage beats Xeris Biopharma on 14 of the 18 factors compared between the two stocks. Get LifeVantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifeVantagePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.26M$6.89B$5.57B$7.83BDividend Yield1.26%3.06%5.11%4.21%P/E Ratio22.097.4422.4418.48Price / Sales0.73242.73394.10103.59Price / Cash19.0365.8538.1834.62Price / Book5.206.516.774.25Net Income$2.94M$143.21M$3.22B$248.23M7 Day Performance-2.37%1.98%1.48%0.89%1 Month Performance-21.66%6.89%3.99%3.53%1 Year Performance100.16%-2.52%16.20%5.08% LifeVantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifeVantage3.9902 of 5 stars$12.37+0.2%$30.50+146.6%+102.8%$155.26M$212.15M22.09260Upcoming EarningsPositive NewsXERSXeris Biopharma3.6014 of 5 stars$4.02-2.2%$6.10+51.7%+161.1%$618.84M$203.07M-8.93290Upcoming EarningsNews CoveragePositive NewsABUSArbutus Biopharma1.9901 of 5 stars$3.21+1.9%$5.50+71.3%+30.0%$614.65M$6.17M-7.4690Positive NewsCDXCChromaDex2.3375 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Upcoming EarningsAnalyst ForecastARVNArvinas3.0543 of 5 stars$8.75+1.7%$34.33+292.4%-69.7%$601.76M$263.40M-3.16420Short Interest ↑News CoverageHigh Trading VolumeKALVKalVista Pharmaceuticals4.3769 of 5 stars$12.01+0.1%$24.83+106.8%+21.3%$597.09MN/A-3.30100Positive NewsTRVITrevi Therapeutics3.6034 of 5 stars$6.02-0.8%$17.56+191.7%+135.8%$582.03MN/A-13.6820Upcoming EarningsNews CoveragePositive NewsKROSKeros Therapeutics3.1014 of 5 stars$14.30+1.6%$40.33+182.1%-74.4%$580.04M$3.55M-2.74100Upcoming EarningsPositive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumePHARPharming Group2.724 of 5 stars$8.15+0.7%$30.00+268.1%-6.6%$554.45M$297.20M-31.35280Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap UpVALNValneva2.523 of 5 stars$6.63-2.4%$16.00+141.3%-14.9%$538.76M$169.58M-51.00700Upcoming EarningsShort Interest ↓ Related Companies and Tools Related Companies Xeris Biopharma Competitors Arbutus Biopharma Competitors ChromaDex Competitors Arvinas Competitors KalVista Pharmaceuticals Competitors Trevi Therapeutics Competitors Keros Therapeutics Competitors VectivBio Competitors Pharming Group Competitors Valneva Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFVN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LifeVantage Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share LifeVantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LFVN Stock Free LFVN Stock Alerts